The brain creates internal 'maps' to help us navigate and learn from our surroundings, but how these maps form remains a challenge to understand.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with ...